Compare PMM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMM | OABI |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 225.9M |
| IPO Year | N/A | N/A |
| Metric | PMM | OABI |
|---|---|---|
| Price | $6.23 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 111.4K | ★ 253.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $27.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.70 | $1.22 |
| 52 Week High | $6.52 | $2.22 |
| Indicator | PMM | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 29.50 |
| Support Level | $6.07 | $1.32 |
| Resistance Level | $6.36 | $1.86 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 83.74 | 0.00 |
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.